{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:33:53Z","timestamp":1790732033136,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11064-025-04555-z","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T09:00:45Z","timestamp":1758186045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stigmasterol Alleviates Levodopa-Induced Dyskinesia in 6-OHDA-Induced Parkinsonian Rats"],"prefix":"10.1007","volume":"50","author":[{"given":"Mayuri","family":"Wankhede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Aswar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4566-7453","authenticated-orcid":false,"given":"Urmila","family":"Aswar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"4555_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00415-008-5004-3","volume":"255","author":"G Alves","year":"2008","unstructured":"Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP (2008) Epidemiology of parkinson\u2019s disease. J Neurol 255:18\u201332","journal-title":"J Neurol"},{"key":"4555_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/jamaneurol.2014.2704","volume":"72","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE, Hazrati L-N, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI (2015) Clinical correlations with lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 72:100\u2013105","journal-title":"JAMA Neurol"},{"key":"4555_CR3","doi-asserted-by":"publisher","first-page":"a008870","DOI":"10.1101\/cshperspect.a008870","volume":"2","author":"J Massano","year":"2012","unstructured":"Massano J, Bhatia KP (2012) Clinical approach to parkinson\u2019s disease: features, diagnosis, and principles of management. Cold Spring Harbor Perspect Med 2:a008870","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"4555_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/jnnp.57.6.672","volume":"57","author":"CD Marsden","year":"1994","unstructured":"Marsden CD (1994) Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 57:672","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4555_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","volume":"991","author":"S Fahn","year":"2003","unstructured":"Fahn S (2003) Description of parkinson\u2019s disease as a clinical syndrome. Ann N Y Acad Sci 991:1\u201314","journal-title":"Ann N Y Acad Sci"},{"key":"4555_CR6","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","volume":"28","author":"C Warren Olanow","year":"2013","unstructured":"Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, Investigators SRiDEiPsD (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing\u2010off in parkinson\u2019s disease. Mov Disord 28:1064\u20131071","journal-title":"Mov Disord"},{"key":"4555_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","volume":"83","author":"B Thanvi","year":"2007","unstructured":"Thanvi B, Lo N, Robinson T (2007) Levodopa-induced dyskinesia in parkinson\u2019s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 83:384\u2013388","journal-title":"Postgrad Med J"},{"key":"4555_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2165\/00023210-200317070-00002","volume":"17","author":"T van Laar","year":"2003","unstructured":"van Laar T (2003) Levodopa-induced response fluctuations in patients with parkinson\u2019s disease: strategies for management. CNS Drugs 17:475\u2013489","journal-title":"CNS Drugs"},{"key":"4555_CR9","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","volume":"9","author":"P Calabresi","year":"2010","unstructured":"Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B (2010) Levodopa-induced dyskinesias in patients with parkinson\u2019s disease: filling the bench-to-bedside gap. Lancet Neurol 9:1106\u20131117","journal-title":"Lancet Neurol"},{"key":"4555_CR10","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s00415-016-8075-6","volume":"263","author":"A Nicoletti","year":"2016","unstructured":"Nicoletti A, Mostile G, Nicoletti G, Arabia G, Iliceto G, Lamberti P, Marconi R, Morgante L, Barone P, Quattrone A (2016) Clinical phenotype and risk of levodopa-induced dyskinesia in parkinson\u2019s disease. J Neurol 263:888\u2013894","journal-title":"J Neurol"},{"key":"4555_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/pr.111.005678","volume":"65","author":"P Huot","year":"2013","unstructured":"Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2013) The Pharmacology of L-DOPA-induced dyskinesia in parkinson\u2019s disease. Pharmacol Rev 65:171\u2013222","journal-title":"Pharmacol Rev"},{"key":"4555_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","volume":"132","author":"MF Bastide","year":"2015","unstructured":"Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut P-O, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R (2015) Pathophysiology of L-dopa-induced motor and non-motor complications in parkinson\u2019s disease. Prog Neurobiol 132:96\u2013168","journal-title":"Prog Neurobiol"},{"key":"4555_CR13","doi-asserted-by":"publisher","first-page":"1253273","DOI":"10.3389\/fimmu.2023.1253273","volume":"14","author":"F Zhang","year":"2023","unstructured":"Zhang F, Liu M, Tuo J, Zhang L, Zhang J, Yu C, Xu Z (2023) Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation. Front Immunol 14:1253273","journal-title":"Front Immunol"},{"key":"4555_CR14","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00702-018-1874-4","volume":"125","author":"A Pisanu","year":"2018","unstructured":"Pisanu A, Boi L, Mulas G, Spiga S, Fenu S, Carta AR (2018) Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function. J Neural Transm 125:1287\u20131297","journal-title":"J Neural Transm"},{"key":"4555_CR15","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1093\/brain\/awr165","volume":"134","author":"KE Ohlin","year":"2011","unstructured":"Ohlin KE, Francardo V, Lindgren HS, Sillivan SE, O\u2019Sullivan SS, Luksik AS, Vassoler FM, Lees AJ, Konradi C, Cenci MA (2011) Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain 134:2339\u20132357","journal-title":"Brain"},{"key":"4555_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.nbd.2014.10.017","volume":"73","author":"M Bortolanza","year":"2015","unstructured":"Bortolanza M, Cavalcanti-Kiwiatkoski R, Padovan-Neto FE, da-Silva CA, Mitkovski M, Raisman-Vozari R, Del-Bel E (2015) Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of parkinson\u2019s disease. Neurobiol Dis 73:377\u2013387","journal-title":"Neurobiol Dis"},{"key":"4555_CR17","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/mds.27799","volume":"34","author":"L Boi","year":"2019","unstructured":"Boi L, Pisanu A, Greig NH, Scerba MT, Tweedie D, Mulas G, Fenu S, Carboni E, Spiga S, Carta AR (2019) Immunomodulatory drugs alleviate l-dopa\u2010induced dyskinesia in a rat model of parkinson\u2019s disease. Mov Disord 34:1818\u20131830","journal-title":"Mov Disord"},{"key":"4555_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fneur.2014.00095","volume":"5","author":"CJ Finlay","year":"2014","unstructured":"Finlay CJ, Duty S, Vernon AC (2014) Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies. Front Neurol 5:95","journal-title":"Front Neurol"},{"key":"4555_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fncir.2016.00105","volume":"10","author":"Q Wang","year":"2016","unstructured":"Wang Q, Zhang W (2016) Maladaptive synaptic plasticity in L-DOPA-induced dyskinesia. Front Neural Circuits 10:105","journal-title":"Front Neural Circuits"},{"key":"4555_CR20","doi-asserted-by":"publisher","first-page":"8590578","DOI":"10.1155\/2016\/8590578","volume":"2016","author":"S Manoharan","year":"2016","unstructured":"Manoharan S, Guillemin GJ, Abiramasundari RS, Essa MM, Akbar M, Akbar MD (2016) The role of reactive oxygen species in the pathogenesis of alzheimer\u2019s disease, parkinson\u2019s disease, and huntington\u2019s disease: a mini review. Oxidative Med Cell Longev 2016:8590578","journal-title":"Oxidative Med Cell Longev"},{"key":"4555_CR21","doi-asserted-by":"publisher","first-page":"683577","DOI":"10.3389\/fimmu.2021.683577","volume":"12","author":"C-Q Zheng","year":"2021","unstructured":"Zheng C-Q, Fan H-X, Li X-X, Li J-J, Sheng S, Zhang F (2021) Resveratrol alleviates levodopa-induced dyskinesia in rats. Front Immunol 12:683577","journal-title":"Front Immunol"},{"key":"4555_CR22","doi-asserted-by":"publisher","first-page":"100334","DOI":"10.1016\/j.phyplu.2022.100334","volume":"2","author":"P Ashrafi","year":"2022","unstructured":"Ashrafi P, Jahromy MH (2022) Potential efficacy of Nanocurcumin on levodopa-induced dyskinesia in a rat parkinsonian model. Phytomedicine Plus 2:100334","journal-title":"Phytomedicine Plus"},{"key":"4555_CR23","first-page":"1118","volume":"17","author":"S-F Zhang","year":"2018","unstructured":"Zhang S-F, Xie C-L, Lin J-Y, Wang M-H, Wang X-J, Liu Z-G (2018) Lipoic acid alleviates L-DOPA-induced dyskinesia in 6-OHDA parkinsonian rats via anti-oxidative stress. Mol Med Rep 17:1118\u20131124","journal-title":"Mol Med Rep"},{"key":"4555_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neuroscience.2008.07.016","volume":"156","author":"CJ Barnum","year":"2008","unstructured":"Barnum CJ, Eskow KL, Dupre K, Blandino P Jr, Deak T, Bishop C (2008) Exogenous corticosterone reduces l-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1\u03b2. Neuroscience 156:30\u201341","journal-title":"Neuroscience"},{"key":"4555_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11940-025-00833-x","volume":"27","author":"D Power","year":"2025","unstructured":"Power D, Crotty GF (2025) Advances in the Pharmacological management of parkinson\u2019s disease. Curr Treat Options Neurol 27:22","journal-title":"Curr Treat Options Neurol"},{"key":"4555_CR26","doi-asserted-by":"crossref","unstructured":"Antonini A, O\u2019Suilleabhain P, Stocchi F, Landstr\u00f6m J, Waters S, Sonesson C, Tedroff J (2025) Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson\u2019s Disease: A Randomized Phase 2b Trial. Movement Disorders Clinical Practice","DOI":"10.1002\/mdc3.70004"},{"key":"4555_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.expneurol.2005.08.017","volume":"196","author":"F Bibbiani","year":"2005","unstructured":"Bibbiani F, Oh J, Kielaite A, Collins M, Smith C, Chase T (2005) Combined Blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 196:422\u2013429","journal-title":"Exp Neurol"},{"key":"4555_CR28","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/mds.26159","volume":"30","author":"R Pahwa","year":"2015","unstructured":"Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT (2015) Amantadine extended release for levodopa-induced dyskinesia in parkinson\u2019s disease (EASED Study). Mov Disord 30:788\u2013795","journal-title":"Mov Disord"},{"key":"4555_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nrd3430","volume":"10","author":"WG Meissner","year":"2011","unstructured":"Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V (2011) Priorities in parkinson\u2019s disease research. Nat Rev Drug Discovery 10:377\u2013393","journal-title":"Nat Rev Drug Discovery"},{"key":"4555_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.plipres.2015.01.003","volume":"58","author":"T Vanmierlo","year":"2015","unstructured":"Vanmierlo T, Bogie JF, Mailleux J, Vanmol J, L\u00fctjohann D, Mulder M, Hendriks JJ (2015) Plant sterols: friend or foe in CNS disorders? Prog Lipid Res 58:26\u201339","journal-title":"Prog Lipid Res"},{"key":"4555_CR31","first-page":"1","volume":"11","author":"B Saad","year":"2022","unstructured":"Saad B, Nesrine B, Ilhame B, Taoufiq B, Lee L-H, Nasreddine EO, Ryan AS, Goh KW, Ming LC, Abdelhakim B (2022) Health benefits and Pharmacological properties of stigmasterol. Antioxid (Basel) 11:1\u201323","journal-title":"Antioxid (Basel)"},{"key":"4555_CR32","doi-asserted-by":"crossref","unstructured":"Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R, Participants SW (2003) Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. In: Mayo Clinic Proceedings. Elsevier, pp 965\u2013978","DOI":"10.4065\/78.8.965"},{"key":"4555_CR33","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.2174\/0929867325666180706113844","volume":"26","author":"T Dierckx","year":"2019","unstructured":"Dierckx T, Bogie JF, Hendriks JJ (2019) The impact of phytosterols on the healthy and diseased brain. Curr Med Chem 26:6750\u20136765","journal-title":"Curr Med Chem"},{"key":"4555_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11130-016-0574-1","volume":"71","author":"R Shuang","year":"2016","unstructured":"Shuang R, Rui X, Wenfang L (2016) Phytosterols and dementia. Plant Foods Hum Nutr 71:347\u2013354","journal-title":"Plant Foods Hum Nutr"},{"key":"4555_CR35","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1194\/jlr.M017244","volume":"53","author":"T Vanmierlo","year":"2012","unstructured":"Vanmierlo T, Weing\u00e4rtner O, van der Pol S, Husche C, Kerksiek A, Friedrichs S, Sijbrands E, Steinbusch H, Grimm M, Hartmann T (2012) Dietary intake of plant sterols stably increases plant sterol levels in the murine brain. J Lipid Res 53:726\u2013735","journal-title":"J Lipid Res"},{"key":"4555_CR36","doi-asserted-by":"publisher","first-page":"113317","DOI":"10.1016\/j.biopha.2022.113317","volume":"153","author":"F Jie","year":"2022","unstructured":"Jie F, Yang X, Yang B, Liu Y, Wu L, Lu B (2022) Stigmasterol attenuates inflammatory response of microglia via NF-\u03baB and NLRP3 signaling by AMPK activation. Biomed Pharmacother 153:113317","journal-title":"Biomed Pharmacother"},{"key":"4555_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.biopha.2017.08.073","volume":"95","author":"JJ Soares","year":"2017","unstructured":"Soares JJ, Rodrigues DT, Gon\u00e7alves MB, Lemos MC, Gallarreta MS, Bianchini MC, Gayer MC, Puntel RL, Roehrs R, Denardin EL (2017) Paraquat exposure-induced parkinson\u2019s disease-like symptoms and oxidative stress in drosophila melanogaster: neuroprotective effect of Bougainvillea glabra Choisy. Biomed Pharmacother 95:245\u2013251","journal-title":"Biomed Pharmacother"},{"key":"4555_CR38","doi-asserted-by":"publisher","first-page":"4490081","DOI":"10.1155\/2021\/4490081","volume":"2021","author":"D Lin","year":"2021","unstructured":"Lin D, Zeng Y, Tang D, Cai Y (2021) Study on the mechanism of Liuwei Dihuang pills in treating parkinson\u2019s disease based on network Pharmacology. Biomed Res Int 2021:4490081","journal-title":"Biomed Res Int"},{"key":"4555_CR39","doi-asserted-by":"crossref","unstructured":"Lin D, Zeng Y, Tang D, Cai Y (2021) Study on the mechanism of Liuwei Dihuang pill s formula in treating Parkinson. \u2018s Disease Based on Network Pharmacology","DOI":"10.21203\/rs.3.rs-401619\/v1"},{"key":"4555_CR40","first-page":"214","volume":"45","author":"J Lee","year":"2014","unstructured":"Lee J, Weon JB, Ma CJ (2014) Neuroprotective activity of phytosterols isolated from Artemisia apiacea. Korean J Pharmacognosy 45:214\u2013219","journal-title":"Korean J Pharmacognosy"},{"key":"4555_CR41","doi-asserted-by":"publisher","first-page":"153415","DOI":"10.1016\/j.phymed.2020.153415","volume":"81","author":"MN Haque","year":"2021","unstructured":"Haque MN, Hannan MA, Dash R, Choi SM, Moon IS (2021) The potential LXR\u03b2 agonist stigmasterol protects against hypoxia\/reoxygenation injury by modulating mitophagy in primary hippocampal neurons. Phytomedicine 81:153415","journal-title":"Phytomedicine"},{"key":"4555_CR42","doi-asserted-by":"publisher","first-page":"16072","DOI":"10.1523\/JNEUROSCI.1506-13.2013","volume":"33","author":"VK Burg","year":"2013","unstructured":"Burg VK, Grimm HS, Rothhaar TL, Gr\u00f6sgen S, Hundsd\u00f6rfer B, Haupenthal VJ, Zimmer VC, Mett J, Weing\u00e4rtner O, Laufs U (2013) Plant sterols the better cholesterol in alzheimer\u2019s disease? A mechanistical study. J Neurosci 33:16072\u201316087","journal-title":"J Neurosci"},{"key":"4555_CR43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","volume":"15","author":"M Lundblad","year":"2002","unstructured":"Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of parkinson\u2019s disease. Eur J Neurosci 15:120\u2013132","journal-title":"Eur J Neurosci"},{"key":"4555_CR44","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jfca.2006.01.003","volume":"19","author":"K Thaipong","year":"2006","unstructured":"Thaipong K, Boonprakob U, Crosby K, Cisneros-Zevallos L, Byrne DH (2006) Comparison of ABTS, DPPH, FRAP, and ORAC assays for estimating antioxidant activity from guava fruit extracts. J Food Compos Anal 19:669\u2013675","journal-title":"J Food Compos Anal"},{"key":"4555_CR45","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.foodchem.2011.07.127","volume":"130","author":"K Mishra","year":"2012","unstructured":"Mishra K, Ojha H, Chaudhury NK (2012) Estimation of antiradical properties of antioxidants using DPPH assay: A critical review and results. Food Chem 130:1036\u20131043","journal-title":"Food Chem"},{"key":"4555_CR46","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.3390\/pr11082248","volume":"11","author":"\u0130 Gulcin","year":"2023","unstructured":"Gulcin \u0130, Alwasel SH (2023) DPPH radical scavenging assay. Processes 11:2248","journal-title":"Processes"},{"key":"4555_CR47","first-page":"685","volume":"2","author":"S Kushawaha","year":"2011","unstructured":"Kushawaha S, Malpani, Aarti M, Aswaar U, Bodhankar S, Malpani A, Shivakumar S (2011) Effect of different anaesthetic agents on cardiovascular parameters in male Wistar rats. Res J Pharm Biol Chem Sci 2:685\u2013690","journal-title":"Res J Pharm Biol Chem Sci"},{"key":"4555_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12868-015-0163-5","volume":"16","author":"KS Shin","year":"2015","unstructured":"Shin KS, Zhao TT, Park KH, Park HJ, Hwang BY, Lee CK, Lee MK (2015) Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of parkinson\u2019s disease. BMC Neurosci 16:1\u201310","journal-title":"BMC Neurosci"},{"key":"4555_CR49","first-page":"3356","volume":"17","author":"RJ Su","year":"2018","unstructured":"Su RJ, Zhen JL, Wang W, Zhang JL, Zheng Y, Wang XM (2018) Time-course behavioral features are correlated with parkinson\u2019s disease\u2013associated pathology in a 6-hydroxydopamine Hemiparkinsonian rat model. Mol Med Rep 17:3356\u20133363","journal-title":"Mol Med Rep"},{"key":"4555_CR50","doi-asserted-by":"crossref","unstructured":"da Concei\u00e7\u00e3o FS, Ngo-Abdalla S, Houzel J-C, Rehen SK (2010) Murine model for Parkinson\u2019s disease: from 6-OH dopamine lesion to behavioral test. J Vis Exp 35: e1376","DOI":"10.3791\/1376"},{"key":"4555_CR51","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1460-9568.2005.04238.x","volume":"22","author":"GA Metz","year":"2005","unstructured":"Metz GA, Tse A, Ballermann M, Smith LK, Fouad K (2005) The unilateral 6-OHDA rat model of parkinson\u2019s disease revisited: an electromyographic and behavioural analysis. Eur J Neurosci 22:735\u2013744","journal-title":"Eur J Neurosci"},{"key":"4555_CR52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.bbr.2008.12.007","volume":"199","author":"A Klein","year":"2009","unstructured":"Klein A, Wessolleck J, Papazoglou A, Metz GA, Nikkhah G (2009) Walking pattern analysis after unilateral 6-OHDA lesion and transplantation of foetal dopaminergic progenitor cells in rats. Behav Brain Res 199:317\u2013325","journal-title":"Behav Brain Res"},{"key":"4555_CR53","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1166\/jnn.2016.11103","volume":"16","author":"P Umarao","year":"2016","unstructured":"Umarao P, Bose S, Bhattacharyya S, Kumar A, Jain S (2016) Neuroprotective potential of superparamagnetic iron oxide nanoparticles along with exposure to electromagnetic field in 6-OHDA rat model of parkinson\u2019s disease. J Nanosci Nanotechnol 16:261\u2013269","journal-title":"J Nanosci Nanotechnol"},{"key":"4555_CR54","doi-asserted-by":"publisher","first-page":"108771","DOI":"10.1016\/j.neuropharm.2021.108771","volume":"198","author":"R Tohge","year":"2021","unstructured":"Tohge R, Kaneko S, Morise S, Oki M, Takenouchi N, Murakami A, Nakamura M, Kusaka H, Yakushiji Y (2021) Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of parkinson\u2019s disease. Neuropharmacology 198:108771","journal-title":"Neuropharmacology"},{"key":"4555_CR55","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/futurepharmacol3020025","volume":"3","author":"L Akotkar","year":"2023","unstructured":"Akotkar L, Aswar U, Patil R, Kumar D, Aswar M, Pandey J, Gurav S (2023) Antidepressant effect of alpha lipoic acid in rats exposed to chronic unpredictable mild stress: putative role of neurotransmitters and 5ht3 receptor. Future Pharmacol 3:407\u2013425","journal-title":"Future Pharmacol"},{"key":"4555_CR56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pbb.2015.07.003","volume":"136","author":"I Holzmann","year":"2015","unstructured":"Holzmann I, da Silva LM, da Silva JAC, Steimbach VMB, de Souza MM (2015) Antidepressant-like effect of Quercetin in bulbectomized mice and involvement of the antioxidant defenses, and the glutamatergic and oxidonitrergic pathways. Pharmacol Biochem Behav 136:55\u201363","journal-title":"Pharmacol Biochem Behav"},{"key":"4555_CR57","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.fct.2011.03.018","volume":"49","author":"FM El-Demerdash","year":"2011","unstructured":"El-Demerdash FM (2011) Lipid peroxidation, oxidative stress and acetylcholinesterase in rat brain exposed to organophosphate and pyrethroid insecticides. Food Chem Toxicol 49:1346\u20131352","journal-title":"Food Chem Toxicol"},{"key":"4555_CR58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0021-9258(19)50881-X","volume":"195","author":"RF Beers","year":"1952","unstructured":"Beers RF, Sizer IW (1952) A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 195:133\u2013140","journal-title":"J Biol Chem"},{"key":"4555_CR59","doi-asserted-by":"publisher","first-page":"137606","DOI":"10.1016\/j.neulet.2023.137606","volume":"820","author":"P Shukla","year":"2024","unstructured":"Shukla P, Akotkar L, Aswar U (2024) Resveratrol attenuates early life stress induced depression in rats: behavioural and neurochemical evidence. Neurosci Lett 820:137606","journal-title":"Neurosci Lett"},{"key":"4555_CR60","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/1062936X.2015.1095240","volume":"26","author":"A Sarkate","year":"2015","unstructured":"Sarkate A, Murumkar P, Lokwani D, Kandhare A, Bodhankar S, Shinde D, Bothara K (2015) Design of selective TACE inhibitors using molecular Docking studies: synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity. SAR QSAR Environ Res 26:905\u2013923","journal-title":"SAR QSAR Environ Res"},{"key":"4555_CR61","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3109\/13880209.2013.870584","volume":"52","author":"A Visnagri","year":"2014","unstructured":"Visnagri A, Kandhare AD, Chakravarty S, Ghosh P, Bodhankar SL (2014) Hesperidin, a flavanoglycone attenuates experimental diabetic neuropathy via modulation of cellular and biochemical marker to improve nerve functions. Pharm Biol 52:814\u2013828","journal-title":"Pharm Biol"},{"key":"4555_CR62","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0378-4347(97)00126-6","volume":"694","author":"K Thorr\u00e9","year":"1997","unstructured":"Thorr\u00e9 K, Pravda M, Sarre S, Ebinger G, Michotte Y (1997) New antioxidant mixture for long term stability of serotonin, dopamine and their metabolites in automated microbore liquid chromatography with dual electrochemical detection. J Chromatogr B Biomed Sci Appl 694:297\u2013303","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"4555_CR63","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jpba.2014.05.039","volume":"98","author":"GE De Benedetto","year":"2014","unstructured":"De Benedetto GE, Fico D, Pennetta A, Malitesta C, Nicolardi G, Lofrumento DD, De Nuccio F, La Pesa V (2014) A rapid and simple method for the determination of 3, 4-dihydroxyphenylacetic acid, norepinephrine, dopamine, and serotonin in mouse brain homogenate by HPLC with fluorimetric detection. J Pharm Biomed Anal 98:266\u2013270","journal-title":"J Pharm Biomed Anal"},{"key":"4555_CR64","first-page":"23","volume":"1","author":"L Habibi-Nikakhlagh","year":"2013","unstructured":"Habibi-Nikakhlagh L, Nasri S, Roghani M (2013) The effect of Simvastatin in prevention of histological changes of substantia Nigra and behavioral abnormalities in an experimental model of parkinson\u2019s disease in rat. J Basic Clin Pathophysiology 1:23\u201328","journal-title":"J Basic Clin Pathophysiology"},{"key":"4555_CR65","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/j.1471-4159.1993.tb13642.x","volume":"61","author":"C Mytilineou","year":"1993","unstructured":"Mytilineou C, Han SK, Cohen G (1993) Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 61:1470\u20131478","journal-title":"J Neurochem"},{"key":"4555_CR66","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/practneurol-2014-000849","volume":"15","author":"K Ali","year":"2015","unstructured":"Ali K, Morris HR (2015) Parkinson\u2019s disease: chameleons and mimics. Pract Neurol 15:14\u201325","journal-title":"Pract Neurol"},{"key":"4555_CR67","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3233\/JAD-2008-15314","volume":"15","author":"CD Kamat","year":"2008","unstructured":"Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, Hensley K (2008) Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J Alzheimers Dis 15:473\u2013493","journal-title":"J Alzheimers Dis"},{"key":"4555_CR68","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1126\/science.1093131","volume":"303","author":"SW Altmann","year":"2004","unstructured":"Altmann SW, Davis HR Jr, Zhu L-j, Yao X, Hoos LM, Tetzloff G, Iyer SPN, Maguire M, Golovko A, Zeng M (2004) Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201\u20131204","journal-title":"Science"},{"key":"4555_CR69","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1080\/10408398.2020.1867819","volume":"62","author":"F Jie","year":"2022","unstructured":"Jie F, Yang X, Wu L, Wang M, Lu B (2022) Linking phytosterols and oxyphytosterols from food to brain health: origins, effects, and underlying mechanisms. Crit Rev Food Sci Nutr 62:3613\u20133630","journal-title":"Crit Rev Food Sci Nutr"},{"key":"4555_CR70","doi-asserted-by":"publisher","first-page":"BSR20192133","DOI":"10.1042\/BSR20192133","volume":"40","author":"Q Liang","year":"2020","unstructured":"Liang Q, Yang J, He J, Chen X, Zhang H, Jia M, Liu K, Jia C, Pan Y, Wei J (2020) Stigmasterol alleviates cerebral ischemia\/reperfusion injury by attenuating inflammation and improving antioxidant defenses in rats. Biosci Rep 40:BSR20192133","journal-title":"Biosci Rep"},{"key":"4555_CR71","doi-asserted-by":"crossref","unstructured":"Sun J, Li X, Liu J, Pan X, Zhao Q (2019) Stigmasterol exerts neuro-protective effect against ischemic\/reperfusion injury through reduction of oxidative stress and inactivation of autophagy. Neuropsychiatr Dis Treat 15: 2991\u20133001","DOI":"10.2147\/NDT.S220224"},{"key":"4555_CR72","doi-asserted-by":"publisher","first-page":"908","DOI":"10.33594\/000000063","volume":"52","author":"R Ahmad","year":"2019","unstructured":"Ahmad R, Kochumon S, Chandy B, Shenouda S, Koshy M, Hasan A, Arefanian H, Al-Mulla F, Sindhu S (2019) TNF-\u03b1 drives the CCL4 expression in human monocytic cells: involvement of the SAPK\/JNK and NF-\u03baB signaling pathways. Cell Physiol Biochem 52:908\u2013921","journal-title":"Cell Physiol Biochem"},{"key":"4555_CR73","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00394-018-1753-7","volume":"58","author":"M Son","year":"2019","unstructured":"Son M, Wu J (2019) Egg white hydrolysate and peptide reverse insulin resistance associated with tumor necrosis factor-\u03b1 (TNF-\u03b1) stimulated mitogen-activated protein kinase (MAPK) pathway in skeletal muscle cells. Eur J Nutr 58:1961\u20131969","journal-title":"Eur J Nutr"},{"key":"4555_CR74","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1007\/s00429-015-1125-5","volume":"221","author":"D Gagnon","year":"2016","unstructured":"Gagnon D, Gregoire L, Di Paolo T, Parent M (2016) Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys. Brain Struct Function 221:3675\u20133691","journal-title":"Brain Struct Function"},{"key":"4555_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.expneurol.2017.07.017","volume":"297","author":"E Tronci","year":"2017","unstructured":"Tronci E, Napolitano F, Mu\u00f1oz A, Fidalgo C, Rossi F, Bj\u00f6rklund A, Usiello A, Carta M (2017) BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. Exp Neurol 297:73\u201381","journal-title":"Exp Neurol"},{"key":"4555_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12868-018-0478-0","volume":"19","author":"S Leino","year":"2018","unstructured":"Leino S, Kohtala S, Rantam\u00e4ki T, Koski SK, Rannanp\u00e4\u00e4 S, Salminen O (2018) Dyskinesia and brain-derived neurotrophic factor levels after long-term Levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation. BMC Neurosci 19:1\u201310","journal-title":"BMC Neurosci"},{"key":"4555_CR77","first-page":"94756","volume":"9","author":"R Wang","year":"2020","unstructured":"Wang R, Shao M (2020) L-DOPA-elicited abnormal involuntary movements in the rats damaged severely in substantia Nigra by 6-hydroxydopamine. Annals Palliat Med 9:94756\u201394956","journal-title":"Annals Palliat Med"},{"key":"4555_CR78","doi-asserted-by":"crossref","unstructured":"Bakrim S, Benkhaira N, Bourais I, Benali T, Lee L-H, El Omari N, Sheikh RA, Goh KW, Ming LC, Bouyahya A (2022) Health benefits and pharmacological properties of stigmasterol. Antioxidants 11:1912","DOI":"10.3390\/antiox11101912"},{"key":"4555_CR79","doi-asserted-by":"publisher","first-page":"153646","DOI":"10.1016\/j.phymed.2021.153646","volume":"90","author":"N Karim","year":"2021","unstructured":"Karim N, Khan I, Abdelhalim A, Halim SA, Khan A, Al-Harrasi A (2021) Stigmasterol can be new steroidal drug for neurological disorders: evidence of the GABAergic mechanism via receptor modulation. Phytomedicine 90:153646","journal-title":"Phytomedicine"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-025-04555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-025-04555-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-025-04555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:03:13Z","timestamp":1761544993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-025-04555-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4555"],"URL":"https:\/\/doi.org\/10.1007\/s11064-025-04555-z","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the experiments were performed according to the CCSEA (The Committee for Control and Supervision of Experiments on Animals) and were approved by the Institutional Animal Ethical Committee. The IAEC approval No is PCP\/IAEC\/2024\/1\u20132.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"304"}}